PPT-AMR and appropriate use of antimicrobials

Nicola Magrini and Jane Robertson Policy Access and Use Team EMP TBS 4 November 2014 Optimize use Regulatory mechanisms for new antibiotics Effective lowcost tools for diagnosis and susceptibility testing. Sophomores cannot signup for Block 50 or 570 Dining Dollars Plans Regular Meal Plans Fall Spring Total Anytime Dining 100 Dining Dollars and 2 Guest Passes per Sem 3039 3039 6078 14 Meal Plan 250 Dining Dollars and 2 Guest Passes per Sem 3039 3039 ORIGINAL PAPER BY ROUF, I., MUSTAFA, H., XU, M., XU, W., MILLER, R., & GRUTESER, M. . PRESENTATION BY STEVEN ORDAZ. 1. OUTLINE. INTRODUCTION. BACKGROUND. SECURITY ANALYSIS OF AMR METERS. NEIGHBORHOOD MONITORING. nanomagnet. state. Reinier van . Mourik. 1,2. , Charles . Rettner. 1. , . Bert . Koopmans. 2. , . Stuart . Parkin. 1. 1. IBM . Almaden. Research Center, San Jose, CA. 2. Eindhoven University of Technology, Eindhoven, the Netherlands. (AMR) profiling . in . Escherichia coli. from farmed and wild animals in the Mekong delta of Vietnam. Nguyen . Thi. . Nhung. Oxford University Clinical Research Unit, HCMC, Vietnam. Biodiversity and Health Symposium. . Steven Solomon, MD, FACP, FIDSA . Global Public Health Consulting, LLC. Atlanta, GA . 2016 Pork Management Conference. Clearwater, FL. June 15, 2016. . Presentation Outline. A brief, high-level overview of the public health approach to the antibiotic & antimicrobial resistance (AMR) problem . and other Antibiotics. Lower Snake River Compensation Plan . Hatchery Production Planning Meeting. May 15-16, 2012. Judicious Use of Antimicrobials. AVMA . AqVMC. Guidelines 2002, revised 2004. Treat as a Last Resort. GENERAL INFORMATION:. A. Terminolgy:. Bacteriostatic:. . - Prevents multiplication and growth of bacterial organisms, inhibiting its growth will eventually lead to bacterial death. Bactericidal:. - . Nicola . Magrini. and Jane Robertson. Policy, Access and Use Team, EMP. TBS 4 November 2014. Optimize use. Regulatory mechanisms for new antibiotics. Effective low-cost tools for diagnosis and susceptibility testing. a pharmaceutical industry perspective. 17. th. November 2018. Dr Bryan Deane. Dept of Research, Medical & Innovation . Introduction – the ABPI; the biopharmaceutical industry. AMR: the issue. Richard Smith. Reader in Health Economics. School of Medicine, Health Policy & Practice. Overview of lecture. What is antimicrobial resistance (AMR)?. Economic conceptualisation of AMR. Cost of resistance - country, hospital, disease. programs - Update. Laura Marin. Management Board Meeting, 2-3 April 2019, Basel. Countries. Updated information provided. Argentina. Yes. Belgium. Yes. Canada. Yes. Czech Republic. -. Denmark. -. Egypt. – questions: 1. Give some examples of bacteric idal and bacteriostatic groups / individual antimicrobials. 2. Give some examples of antimicrobials of narrow and broad spectrum f activity 3. Name mec Dmitry Makarov. Department of Feed and Feed Additives safety . . ANTIMICROBIAL RESISTANCE (AMR) IS A GLOBAL THREAT TO MANKIND. *. World Health Organization , author. Report on the burden of endemic health care-associated infection worldwide. Geneva: WHO. antibiotics and other antimicrobials becoming less effective. infections being increasingly difficult or impossible to treat.. For patients, this results in prolonged illness and sometimes death.. Learn more about AMR, its impact on the.